Anthony P. Bihl III - Jan 31, 2023 Form 4 Insider Report for MERIDIAN BIOSCIENCE INC (VIVO)

Role
Director
Signature
/s/ F. Mark Reuter, as Attorney-in-Fact for Anthony P. Bihl III
Stock symbol
VIVO
Transactions as of
Jan 31, 2023
Transactions value $
-$196,451
Form type
4
Date filed
1/31/2023, 01:16 PM
Previous filing
Jul 1, 2022
Next filing
Apr 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIVO Common Stock Disposed to Issuer -15.4K -100% 0 Jan 31, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIVO Stock Option (Right to Buy) Disposed to Issuer -$48.2K -4.6K -100% $10.50 0 Jan 31, 2023 Common Stock 4.6K $23.50 Direct F2
transaction VIVO Stock Option (Right to Buy) Disposed to Issuer -$73.3K -5.8K -100% $12.64 0 Jan 31, 2023 Common Stock 5.8K $21.36 Direct F3
transaction VIVO Stock Option (Right to Buy) Disposed to Issuer -$74.9K -5.66K -100% $13.25 0 Jan 31, 2023 Common Stock 5.66K $20.75 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Anthony P. Bihl III is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
F2 The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F3 The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F4 The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.